株式会社フェニックスバイオ

Patient-derived monoclonal antibody neutralizes HCV infection in vitro and vivo without generating escape mutants

Yokokawa, H. Shinohara, M. Teraoka, Y. Imamura, M. Nakamura, N. Watanabe, N. Date, T. Aizaki, H. Iwamura, T. Narumi, H. Chayama, K. Wakita, T.
PLoS One. 2022 Sep 22;17(9):e0274283. doi: 10.1371/journal.pone.0274283. eCollection 2022.

READ MORE(PUB MED)

Prediction of the human pharmacokinetics of epyrifenacil and its major metabolite, S-3100-CA, by a physiologically based pharmacokinetic modeling using chimeric mice with humanized liver

Hirasawa, K. Abe, J. Nagahori, H. Kitamoto, S.
Toxicol Appl Pharmacol. 2022 Mar 15;439:115912. doi: 10.1016/j.taap.2022.115912.

READ MORE(PUB MED)

Discovery of a first-in-class orally available HBV cccDNA inhibitor

Wang, L. Zhu, Q. Zhang, J. D. Zhang, Y. Ni, X. Xiang, K. Jiang, J. Li, B. Yu, Y. Hu, H. Zhang, M. Wu, W. Zeng, J. Yan, Z. Dai, J. Sun, K. Zhang, X. Chen, D. Feng, S. Sach Peltason, L. Young, J. A. T. Gao, L.
J Hepatol. 2022 Dec 29:S0168-8278(22)03466-3. doi: 10.1016/j.jhep.2022.12.014.

READ MORE(PUB MED)

Characterization and Prevention of Hypovitaminosis C in Chimeric Mice with Humanized Livers

Touchette, Erin K. Bates, Maria C. Johnson, Mitch C. O’Brien, Tracy C. Melton, Roger J. Long, Kelly R. Kakuni, Masakazu, Baginski, Matthew, Radiloff, Daniel R. Sagartz, John E.
Comparative Medicine 2022, 72(6): 355-363.

READ MORE(PUB MED)

Characterization of a KDM5 small molecule inhibitor with antiviral activity against hepatitis B virus

Gilmore, S. A. Tam, D. Cheung, T. L. Snyder, C. Farand, J. Dick, R.Matles, M. Feng, J. Y.Ramirez, R.Li, L. Yu, H. Xu, Y.Barnes, D. Czerwieniec, G. Brendza, K. M. Appleby, T. C. Birkus, G. Willkom, M. Kobayashi, T. Paoli, E. Labelle, M. Boesen, T.Tay, C. H. Delaney, W. E. thNotte, G. T. Schmitz, U. Feierbach, B.
PLoS One. 2022 Dec 7;17(12):e0271145. doi: 10.1371/journal.pone.0271145. eCollection 2022.

READ MORE(PUB MED)

Physiologically based pharmacokinetic modeling for quantitative prediction of exposure to a human disproportionate metabolite of the selective Na(v)1.7 inhibitor DS-1971a, a mixed substrate of cytochrome P450 and aldehyde oxidase, using chimeric mice with humanized liver

Asano, D. Nakamura, K. Nishiya, Y. Shiozawa, H. Takakusa, H. Shibayama, T. Inoue, S. I. Shinozuka, T. Hamada, T. Yahara, C. Watanabe, N. Yoshinari, K.
Drug Metab Dispos. 2023 Jan;51(1):67-80. doi: 10.1124/dmd.122.001000. Epub 2022 Oct 23.

READ MORE(PUB MED)

Designing receptor agonists with enhanced pharmacokinetics by grafting macrocyclic peptides into fragment crystallizable regions

Sakai, K. Sugano-Nakamura, N. Mihara, E. Rojas-Chaverra, N. M. Watanabe, S. Sato, H. Imamura, R. Voon, D. C. Sakai, I. Yamasaki, C. Tateno, C. Shibata, M. Suga, H. Takagi, J. Matsumoto, K.
Nat Biomed Eng. 2022 Nov 7. doi: 10.1038/s41551-022-00955-6.

READ MORE(PUB MED)

Evaluation of the mode of action and human relevance of liver tumors in male mice treated with epyrifenacil

Fukunaga, S. Ogata, K. Eguchi, A. Matsunaga, K. Sakurai, K. Abe, J. Cohen, S. M. Asano, H.
Regul Toxicol Pharmacol. 2022 Oct 6;136:105268. doi: 10.1016/j.yrtph.2022.105268.

READ MORE(PUB MED)

Letrozole ameliorates liver fibrosis through the inhibition of the CTGF pathway and 17β-hydroxysteroid dehydrogenase 13 expression

Sakai, N. Kamimura, K. Miyamoto, H. Ko, M. Nagoya, T. Setsu, T. Sakamaki, A. Yokoo, T. Kamimura, H. Soki, H. Tokunaga, A. Inamine, T. Nakashima, M. Enomoto, H. Kousaka, K. Tachiki, H.
J Gastroenterol. 2022 Oct 27. doi: 10.1007/s00535-022-01929-w.

READ MORE(PUB MED)

Targeting lipid biosynthesis pathways for hepatitis B virus cure

Hyrina, A. Burdette, D. Song, Z. Ramirez, R. Okesli-Armlovich, A. Vijayakumar, A. Bates, J. Trevaskis, J. L. Fletcher, S. P. Lee, W. A. Holdorf, M. M.
PLoS One. 2022 Aug 4;17(8):e0270273. doi: 10.1371/journal.pone.0270273. eCollection 2022.

READ MORE(PUB MED)

Downregulation of CYP17A1 by 20-hydroxyecdysone: plasma progesterone and its vasodilatory properties

Aljaber, M. Y. Orie, N. N. Raees, A. Kraiem, S. Al-Jaber, M. Samsam, W. Hamza, M. M. Abraham, D. Kneteman, N. M. Beotra, A. Mohamed-Ali, V. Almaadheed, M.
Future Sci OA. 2022 Jul 7;8(6):FSO805. doi: 10.2144/fsoa-2022-0006. eCollection 2022 Jul.

READ MORE(PUB MED)

Signature of chronic hepatitis B virus infection in nails and hair

Komatsu, H. Inui, A. Odmaa, E. Ito, Y. Hoshino, H. Umetsu, S. Tsunoda, T. Fujisawa, T.
BMC Infect Dis. 2022 May 4;22(1):431. doi: 10.1186/s12879-022-07400-8.

READ MORE(PUB MED)

Assessment of metabolic activation of felbamate in chimeric mice with humanized liver in combination with in vitro metabolic assays

Sato, K. Sanoh, S. Ishida, Y. Tateno, C. Ohta, S. Kotake, Y.
J Toxicol Sci. 2022;47(7):277-288. doi: 10.2131/jts.47.277.

READ MORE(PUB MED)

IL-31 Levels Correlate with Pruritus in Patients with Cholestatic and Metabolic Liver Diseases and is FXR Responsive in NASH

Xu, J. Wang, Y. Khoshdeli, M. Peach, M. Chuang, J. C. Lin, J. Tsai, W. W. Mahadevan, S. Minto, W. Diehl, L. Gupta, R. Trauner, M. Patel, K. Noureddin, M. Kowdley, K. V. Gulamhusein, A. Bowlus, C. L. Huss, R. S. Myers, R. P. Chung, C. Billin, A. N.
Hepatology. 2022 Jun 10. doi: 10.1002/hep.32599.

READ MORE(PUB MED)

Insights from a high-fat diet fed mouse model with a humanized liver

Saxena, R. Nassiri, M. Yin, X. M. Morral, N.
PLoS One. 2022 May 9;17(5):e0268260. doi: 10.1371/journal.pone.0268260. eCollection 2022.

READ MORE(PUB MED)

Ongoing viral replication and production of infectious virus in patients with chronic hepatitis B virus suppressed below the limit of quantitation on long-term nucleos(t)ide therapy

Burdette, D. L. Lazerwith, S. Yang, J. Chan, H. L. Y. Delaney Iv, W. E. Fletcher, S. P. Cihlar, T. Feierbach, B.
PLoS One. 2022 Apr 1;17(4):e0262516. doi: 10.1371/journal.pone.0262516.

READ MORE(PUB MED)

HBV upregulates TRAIL-R3 expression in hepatocytes for escaping both cell apoptosis and suppression of their replication by TRAIL

Suehiro, Y. Tsuge, M. Kurihara, M. Uchida, T. Fujino, H. Ono, A. Yamauchi, M. Makokha, G. N. Nakahara, T. Murakami, E. Abe-Chayama, H. Kawaoka, T. Miki, D. Imamura, M. Aikata, H. Hayes, C. N. Fujita, T. Chayama, K.
J Infect Dis. 2022 Feb 28. pii: 6534478. doi: 10.1093/infdis/jiac044.

READ MORE(PUB MED)

Droplet digital PCR assay provides intrahepatic HBV cccDNA quantification tool for clinical application

Hayashi, S. Isogawa, M. Kawashima, K. Ito, K. Chuaypen, N. Morine, Y. Shimada, M. Higashi-Kuwata, N. Watanabe, T. Tangkijvanich, P. Mitsuya, H. Tanaka, Y.
Sci Rep. 2022 Feb 8;12(1):2133. doi: 10.1038/s41598-022-05882-9.

READ MORE(PUB MED)

Simultaneous Measurement of Mouse and Human Albumin in Chimeric Mice with Humanized Livers

France Landry1, Hong Shen2, Yueping Zhang2, Asako Uchiyama3, Yoshinari Miyata4, Yoshio Morikawa4, Beth Joshi2, and Petia Shipkova1
Bioanalysis. 2022 Mar;14(5):267-278. doi: 10.4155/bio-2021-0250. Epub 2022 Feb 23.

READ MORE(PUB MED)

ヒト肝細胞キメラマウスを利用したB型肝炎ウイルス/D型肝炎ウイルス共感染モデル

加国雅和
Medical Science Digest（MSD)　2021；47（14）：26－27

研究発表

Patient-derived monoclonal antibody neutralizes HCV infection in vitro and vivo without generating escape mutants

Prediction of the human pharmacokinetics of epyrifenacil and its major metabolite, S-3100-CA, by a physiologically based pharmacokinetic modeling using chimeric mice with humanized liver

Discovery of a first-in-class orally available HBV cccDNA inhibitor

Characterization and Prevention of Hypovitaminosis C in Chimeric Mice with Humanized Livers

Characterization of a KDM5 small molecule inhibitor with antiviral activity against hepatitis B virus

Physiologically based pharmacokinetic modeling for quantitative prediction of exposure to a human disproportionate metabolite of the selective Na(v)1.7 inhibitor DS-1971a, a mixed substrate of cytochrome P450 and aldehyde oxidase, using chimeric mice with humanized liver

Designing receptor agonists with enhanced pharmacokinetics by grafting macrocyclic peptides into fragment crystallizable regions

Evaluation of the mode of action and human relevance of liver tumors in male mice treated with epyrifenacil

Letrozole ameliorates liver fibrosis through the inhibition of the CTGF pathway and 17β-hydroxysteroid dehydrogenase 13 expression

Targeting lipid biosynthesis pathways for hepatitis B virus cure

Downregulation of CYP17A1 by 20-hydroxyecdysone: plasma progesterone and its vasodilatory properties

Signature of chronic hepatitis B virus infection in nails and hair

Assessment of metabolic activation of felbamate in chimeric mice with humanized liver in combination with in vitro metabolic assays

IL-31 Levels Correlate with Pruritus in Patients with Cholestatic and Metabolic Liver Diseases and is FXR Responsive in NASH

Insights from a high-fat diet fed mouse model with a humanized liver

Ongoing viral replication and production of infectious virus in patients with chronic hepatitis B virus suppressed below the limit of quantitation on long-term nucleos(t)ide therapy

HBV upregulates TRAIL-R3 expression in hepatocytes for escaping both cell apoptosis and suppression of their replication by TRAIL

Droplet digital PCR assay provides intrahepatic HBV cccDNA quantification tool for clinical application

Simultaneous Measurement of Mouse and Human Albumin in Chimeric Mice with Humanized Livers

ヒト肝細胞キメラマウスを利用したB型 肝炎ウイルス/D型肝炎ウイルス共感染モデル

ヒト肝細胞キメラマウスを利用したB型肝炎ウイルス/D型肝炎ウイルス共感染モデル